ProteoFormiX provides a top‑down mass‑spectrometry platform that characterizes intact proteoforms in low‑volume tissue and biofluid samples, generating quantitative proteoform profiles linked to disease phenotypes. The service delivers validated multi‑disorder biomarker panels and assay concepts for pharmaceutical, diagnostic and research partners to accelerate diagnostic development.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic workflows often rely on single-analyte tests that require relatively large sample volumes and lack the sensitivity to detect disease-specific proteoforms, limiting the ability to diagnose multiple disorders rapidly and accurately from limited patient material.
Solution
ProteoFormiX operates a translational biomarker discovery platform built on top‑down proteomics. By applying proprietary, state‑of‑the‑art mass‑spectrometry techniques, the platform directly characterizes intact proteoforms—such as disease‑associated peptides—in clinical tissues and biofluids. This approach enables the identification of highly specific biomarker signatures that can be measured from small‑volume patient samples, supporting simultaneous detection of multiple disorders. The resulting biomarker panels are delivered to partners as validated assay concepts ready for downstream diagnostic development.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, clinical diagnostic developers, and academic research groups seeking validated proteoform‑based biomarkers for multi‑disease testing from limited patient samples.
Features
- Top‑down mass‑spectrometry workflow that preserves proteoform integrity for precise peptide identification
- Proprietary sample‑preparation chemistry optimized for low‑volume tissue and biofluid specimens
- High‑throughput data acquisition and automated deconvolution pipelines to generate quantitative proteoform profiles
- Bioinformatic analytics suite that links proteoform patterns to disease phenotypes and constructs multi‑disorder biomarker panels
- End‑to‑end validation pipeline, including assay feasibility assessment and clinical relevance scoring
- Secure, HIPAA‑compliant data handling and cloud‑based result delivery for partner integration
- Compatibility with standard clinical laboratory instrumentation and downstream assay platforms